39 peer-reviewed studies · Evidence score: 7/10
Liang H et al. • Renal failure (2025)
Through rigorous experimental validation, our study demonstrates AS's significant clinical efficacy in managing DN.
Tang S et al. • Frontiers in endocrinology (2025)
TCM has demonstrated considerable effectiveness in managing diabetes.
Li Q et al. • Naunyn-Schmiedeberg's archives of pharmacology (2025)
The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Lin YQ et al. • Renal failure (2024)
The astragalus-RAAS blocker combination treatment is safe and improves outcomes; however, rigorous randomized, large-scale, multi-center, double-blind trials are needed to evaluate its efficacy and safety in stage III DN.
Chen S et al. • International wound journal (2024)
International Wound Journal published by Medicalhelplines.com Inc and John Wiley & Sons Ltd.
Zhou Z et al. • Scientific reports (2023)
This meta-analysis examined the effects of Astragalus.
Wang D et al. • Medicine (2023)
Adjunctive use of A membranaceus preparations combined with supportive care or immunosuppressive therapy have a promising treatment for improving complete response rate, partial response rate, serum albumin, and reducing proteinuria, serum creatinine levels compared to immunosuppressive therapy in people with MN being at moderate-high risk for disease progression.
Huai B et al. • Frontiers in endocrinology (2023)
The combination of traditional Chinese medicine adjuvant therapy has a good curative effect on PDR patients.
Hong KF et al. • Journal of integrative and complementary medicine (2024)
PROSPERO REGISTRATION NUMBER CRD42022338491.
Pang XM et al. • Medicine (2022)
The traditional Chinese medicinal preparation containing astragalus can effectively alleviate the clinical symptoms of RILI, reduce the toxic side effects, and is safe to use in clinic.
Zheng Q et al. • Oxidative medicine and cellular longevity (2020)
In conclusion, the findings suggested that AM is a cardioprotection candidate drug for VM.
Zheng Y et al. • The American journal of Chinese medicine (2020)
However, considering the low quality, small size, and high risk of the studies identified in this meta-analysis, higher methodological quality, rigorously designed RCTs with large sample sizes are needed to confirm the results.
Zhang L et al. • Journal of ethnopharmacology (2019)
The low quality of evidence suggested that adjunctive use of A. membranaceus preparations in addition to conventional therapies may be effective and tolerated for short-term reduction of albuminuria, proteinuria, and serum creatinine in DKD patients.
Li M et al. • Journal of ethnopharmacology (2011)
Astragalus injection had more therapeutic effect in DN patients including renal protective effect (BUN, SCr, CCr and urine protein) and systemic state improvement (serum albumin level) compared with the control group.
Xu L et al. • Metabolic brain disease (2020)
However, stronger evidence is needed for a promising conclusion and more rigorous designs of RCTs are merited in the future.
Sheng X et al. • Integrative cancer therapies (2025)
Registered 20 July 2023.
Zhang X et al. • Complementary medicine research (2023)
This systematic review and meta-analysis provide evidence supporting the immunomodulatory effects of Astragalus on humoral and cellular response.
Josa E et al. • Nutrients (2024)
These results suggest that bioactive compounds of plant-based foods and medicinal plants have promising effects in terms of preventing or treating CKD progression and appear to improve inflammation and antioxidant capacity and support cardiovascular benefits and renoprotective effects; however, it is recommended that further studies be carried out.
Huang M et al. • Nutrients (2023)
Herbal medicine modulates GM and is associated with increased genera in obese individuals.
Han J et al. • Journal of ethnopharmacology (2024)
TMs appear to be effective and safe in the prevention of chronic OIPN, especially severe chronic OIPN.